Background: Induction chemotherapy (ICT) with docetaxel, cisplatin and fluorouracil (TPF) followed by radiotherapy is an effective treatment option for locally advanced head and neck cancer. This phase II study investigated the effectivity of a splitdose TPF ICT before surgery for locally advanced resectable (stage III/IVA) oral and oropharyngeal cancer. Responders (reduction tumor volume 30% after first cycle) received three 3-week cycles and non-responders only one cycle before surgery and postoperative radio(chemo)therapy (RCT). The primary endpoint was progression-free survival rate after 24 months. Secondary endpoints were amongst others overall survival, histopathological response to ICT, toxicity, quality of life and swallowing function.
Introduction
Surgery in combination with postoperative radiotherapy or radiochemotherapy is one treatment strategy for locoregionally advanced resectable oral and oropharyngeal cancer [1] . Induction chemotherapy (ICT) has regained interest by the evaluation of the combination of docetaxel, platinum and 5-fluorouracil (TPF) followed by non-surgical management in phase III trials [2] . TPF ICT before radiotherapy or radiochemotherapy remains controversial because the benefit in comparison to current treatment still is unclear [3, 4] . TPF ICT before surgery has so far been analyzed only in two prospective controlled studies. A randomized phase III trial of TPF ICT in surgically managed locally advanced oral squamous cell carcinoma found favorable pathologic response after ICT but no improvement in overall survival (OS) [5, 6] . The DeLOS II phase II trial started with a TPF ICT with or without cetuximab for patients with only by laryngectomy operable carcinoma of the larynx/hypopharynx [7] . Due to five toxic deaths, the ICT regime was changed from TPF to TF. This observation led to discussions about the feasibility of TPF in German head and neck cancer patients.
Before the present phase II trial, we therefore carried out a phase I dose escalation trial to investigate the safety of combining a split-dose TPF regime as ICT followed by surgery and postoperative radiotherapy or radiochemotherapy in patients with locally advanced oral and oropharyngeal cancer [8] . Splitting the dosage of TPF has been shown to reduce the toxicity without reduction of effectiveness in gastric cancer [9] . Furthermore, not to unnecessarily burden non-responders to ICT, a short-induction concept was introduced: only responders to the first cycle of split-dose TPF received further two cycles. Non-responders received a surgical resection of the primary tumor and neck dissection. Our phase I showed that a split-dose regime of TPF with a dose of 30 mg/m 2 docetaxel per week before surgery was feasible and well tolerated [8] . Here, we report on the results of the subsequent phase II trial.
Methods
This phase II multicenter study was conducted at seven institutions in Germany (ClinicalTrials.gov; NCT01108042). This trial was preceded by a phase I study [8] . The protocol was centrally approved by the ethics committee of the Friedrich-Schiller-University Jena, and adopted by the ethics committee of all study centers. The protocol was conformed to the Declaration of Helsinki and its amendments. All patients provided written informed consent before registration. Patients were included from August 2010 to August 2013 and have been observed for 24 months or death.
Patient eligibility
Patients aged 18 and 80 years were eligible for inclusion if a histologically confirmed resectable squamous cell carcinoma of the oral cavity (excluding the lip), or of the oropharynx had been diagnosed. Tumors were judged resectable when an R0 resection was likely to be achieved.
Tumors were included if they were classified as any cTcN2M0, any cTcN3M0, cT3 and cN0-1M0, cT4 and cN0-1M0 (American Joint Committee on Cancer; AJCC). Other eligibility criteria are listed in supplementary Material S1, available at Annals of Oncology online.
Study design
This trial was an open-label, multicenter, prospective, three-modality phase II study. The study was designed as a one armed single therapy trial with a decision tree based on response to a single cycle of chemotherapy. The primary objective was to determine the 2-year progression-free survival (PFS) rate. Secondary objectives included determination due toxicity, 2-year OS, response to the first cycle of ICT, proportion of R1 resections and close margins (<5 mm), quality of life and swallowing function.
All patients received a panendoscopy with tattooing of the tumor margins to provide original dimensions for surgery and that surgery included the original dimensions after ICT. Patients had to follow the treatment plan as illustrated in supplementary Figure S1 , available at Annals of Oncology online. TISOC-1 started with a split-dose regime of TPF. Each chemotherapy cycle lasted 3 weeks. Antibiotic prophylaxis was mandatory during the first cycle. During the first cycle, docetaxel and cisplatin were given on days 1 and 8, and 5-fluorouracil as a 24-h infusion on days 1 and 8. Tumor response was evaluated on day 21 using primarily a clinical examination with endoscopy of the primary tumor. Tumor response to chemotherapy was defined as a reduction of the tumor volume 30%. Response definitions and criteria for continuation of the ICT are explained in supplementary Material S2, available at Annals of Oncology online. All responders received two more cycles of split-TPF, i.e. responders underwent surgery after three cycles and non-responders after one cycle of ICT.
Due to the results of the phase I study [8] , the dose level for docetaxel was fixed to 30 mg/m 2 Surgery was recommended to be carried out 2-5 weeks after last chemotherapy. Details on surgery, radiotherapy or radiochemotherapy and risk criteria are listed in supplementary Material S3, available at Annals of Oncology online. Tumors were tested for p16 and human papillomavirus (HPV) DNA by PCR as described previously [10] .
Study evaluations
Study evaluations were carried out before, during and after completion of therapy. Details can be found in in supplementary Material S4, available at Annals of Oncology online. Disease progression, toxicity, swallowing function assessed using the penetration-aspiration-scale (PAS) and Prosiegel's grading [11, 12] , quality of life using the EORTC QLQ-H&N35 questionnaire [13] , and survival were subsequently evaluated every 3 months for 1 year and at 6-month intervals in the second year.
Statistics
Data analyses were carried out using the SAS V R System Version 9.3 (SAS Institute Inc., Cary, NC). For categorical variables, summary tabulations of the number and percentage within each category (with a category for missing data) of the parameter were created. For continuous variables, the mean, median, and standard deviation were calculated as well as the number of missing values.
The power analysis is explained in in supplementary Material S5, available at Annals of Oncology online. PFS in months was measured from the date of first ICT dose given until the date of progression or death. PFS for patients without progression or death was censored at their date of last contact. OS in months was measured from the date of first dose given until the date of death. Survival time for patients not known to have died was censored at their date of last contact. All event-related data were analyzed by Kaplan-Meier methods and compared using the log-rank test. To control a possible lead bias between responders and non-responders, we repeated all calculation for PFS and OS with date of surgery instead of date of first dose of chemotherapy as starting point. For comparisons of categorical data between subgroups, v 2 -test or Fisher's exact test were used. For comparisons of continuous data Mann-Whitney U-test were used. P-values were two sided.
Results

Patient demographics
Fifty-four (54) patients out of 59 enrolled patients obtained the complete tri-modal treatment and formed the per-protocol study group (4 responders and 1 non-responder did not pass the complete treatment protocol). Baseline characteristics are given in Table 1 . The mean treatment time from start of ICT to the end of postoperative radio(chemo)therapy (RCT) was 5.1 6 0.9 months (4.0 6 0.5 months for non-responders, 5.4 6 0.7 months for responders).
Response to ICT and toxicity
In the per-protocol study group 16 patients (30%) showed no reduction of the tumor volume of 30% after the first cycle of ICT and were classified as non-responders. Thirty-eight patients (70%) were classified as responders. Out of the non-responders 12 patients had a SD and 4 patients a PD. Out of the responders 1 patient had a CR and 37 a PR. The non-responders (54.4 6 7.2 year) were younger than the responders (58.9 6 7.1 years; P ¼ 0.032). Otherwise, the baseline characteristics were not different (Table 1) . Administration and dosages of ICT by treatment group are presented in supplementary Tables S1 and S2, available at Annals of Oncology online. Mean Karnofsky index and swallowing function after ICT were not different between responders and nonresponders (cf. supplementary Table S2 , available at Annals of Oncology online). The main grade 3/4 toxicities of ICT were neutropenia (26% of patients), diarrhea (6%), and reduced white blood cell count (6%). Supplementary Table S3, available at Annals of Oncology online lists all adverse events.
Surgery and histopathology
Extraoral surgery (46%) and transoral surgery (54%) were carried out in most cases in combination with bilateral neck dissection (93%; ipsilateral neck dissection in 7%). Thirty-five percentage of the patients needed a flap reconstruction of the primary tumor defect. Complication rate and postsurgical swallowing function were not different between responders and non-responders (supplementary Table S4 , available at Annals of Oncology online). A histopathological complete remission (ypCR) of primary tumor and neck metastases was seen in 22% of the patients. The rate of ypCR of the primary tumor was higher in responders (P ¼
Postoperative radiotherapy or radiochemotherapy and toxicity
Due to the histopathological results, 63% of the patients were classified as low risk and 37% as high risk. Major radiotherapy protocol deviations did not occur. All adverse events during postoperative RCT for responders and non-responders are summarized in supplementary Table S6 , available at Annals of Oncology online. The most important grade 3/4 toxicities were mucositis (13% of patients), dermatitis (7%) and fatigue (6%).
PFS and OS
At the end of follow-up, 6 patients (3 responders and 3 nonresponders) had a tumor progression and 10 patients died (5 responders and 5 non-responders). The sites of failure were a local progress in four cases and a distant failure in two cases. Mean PFS was 36.0 months [95% confidence interval (CI) ¼ 31.8-40.1]. Median values could not be calculated because the probability of PFS (and also of OS) did not fall below 50% during the 24-month follow-up. The PFS rate after 24 months was 88.5% for responders and 60.6% for non-responders. The PFS rate was significantly higher for responders than for non-responders (P ¼ 0.005; Figure 1 ). Mean PFS for responders was 38.8 months (CI ¼ 34.6-43.0) and for non-responder it was 26.1 months (CI ¼ 19.9-32.2). Beyond response to ICT, the tumor site was the only other significant prognostic factor for PFS in the univariate analysis (supplementary Table S7 , available at Annals of Oncology online). Patients with cancer of the oral cavity had a lower PFS rate than patients with oropharyngeal cancer (P ¼ 0.006).
The OS rate after 24 months was 97.3% for responders and 73.7% for non-responders. The OS rate was significantly higher for responders than for non-responders (P ¼ 0.032; Figure 1 ). Mean OS was 38.1 months (CI ¼ 34.3-41.9). Mean OS for responders was 39.9 months (CI ¼ 36.1-43.8) and for nonresponders it was 29.6 months (CI ¼ 24.1-35.1). Beyond response to ICT, the tumor volume and the tumor site were the only other significant prognostic factors for OS in the univariate analysis (supplementary Table S7 , available at Annals of Oncology online). A tumor volume lower than the median volume of 9 ml was associated to lower OS (P ¼ 0.015). Patients with cancer of the oral cavity had a lower OS rate than patients with oropharyngeal cancer (P ¼ 0.015).
These results were mostly confirmed by the multivariate analysis for independent risk factors (supplementary Table S8 In addition to the per-protocol analysis, also an intention-totreat analysis on PFS and OS was carried out (supplementary  Tables S12-S14 and Figures S2 and S3 in Results S1, available at Annals of Oncology online). In the intention-to treat analysis, there still was a significant better PFS in responders than in nonresponders (P ¼ 0.048), but OS was not different (P ¼ 0.209). Here, the multivariate analysis showed again that responders had a better PFS than non-responders but not better OS.
Furthermore, using time of surgery as starting point instead of time of ICT, PFS was still better for responders than for non-responders (supplementary Table S15 and Figure S4 in Results S2, available at Annals of Oncology online). Volume of the primary tumor. WHO definition for anemia: women <7.5 mmol/l, and men <8.1 mmol/l. SD, standard deviation; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; PAS, penetration-aspiration-scale; AJCC, American Joint Committee on Cancer; HPV, human papilloma virus.
Assessments of quality of life and swallowing
With exception of social eating all other baseline EORTC QLQ-HN35 subscales on quality of life were not different between responders and non-responders (supplementary Table S9 , available at Annals of Oncology online). During the follow-up up to 24 months after therapy there was no difference in quality of life scores again with one exception (supplementary Table S10 , available at Annals of Oncology online): Speech function was lower in non-responders 18 month after end of therapy. Swallowing function measured by PAS grading and the Prosiegel scale was not different between responders and non-responders from the end of therapy until the last follow-up visit 24 months after therapy (supplementary Table S11 , available at Annals of Oncology online).
Discussion
The present trial confirmed the feasibility of the unusually longtri-modal treatment approach (median treatment time for responders: 5.5 months). The clinicoradiologic overall response rate to TPF (as for split TPF in the present trial) for head and neck cancer is about 70%-80% (complete response: 9%-17%; [7, 24] . The phase III trial of Zhong et al. was the only other prospective clinical trial investigating TPF before surgery [5, 6] . Zhong et al. used two cycles of standard TPF dosage in oral cancer patients only and reached an ypT0 and an ypN0 rate of 12.4% and 45.5%, respectively. In the present study the ypT0 and ypN0 rate for responders were 6.3% and 21.4%, respectively. Hence, the clinicoradiologic assessment seems to overestimate the histopathological tumor response. Recently, we have shown that tumor cell remnants in the primary tumor are randomly distributed in the necrotic former tumor area [14] . Nevertheless, the presented ICT strategy seems to decrease highrisk constellations for responders (only 21% high risk) as we would expect about half of the patients with high-risk post-surgical constellation after surgery without ICT [15] . Nevertheless, if high risk criteria are still present after ICT, a downsized chemotherapy during postoperative radiotherapy is not justified.
Biomarkers like GDF15 or annexin A1 expression in the tumor, tumor invasion, or lower amount of circulating tumor cells, are predictive for benefit from TPF induction [14, [16] [17] [18] . No marker has been established in clinical routine yet. The role of HPV remains unclear. HPV-positive tumors might respond better to TPF-induction [19, 20] . The rate of missing data on HPV positivity was too high in the present study to answer this question. HPV status should be obtained for any further trials. Surprisingly, patients with higher tumor volume had better OS. We do not have an explanation for this observation. Against this background, the concept of chemoselection is of interest. Using the primary tumor's response after one cycle of ICT was primarily introduced in organ preservation concepts to select responders for definitive radiochemotherapy while reserving primary surgical management for non-responders [7, [20] [21] [22] . Chemoselection can select patients profiting from ICT and limits the morbidity for non-responders. Obviously, this holds true also for chemoselection before surgery. This has been shown in the present study and also for laryngeal cancer [23] .
The split-dose strategy also spared toxicity. Using the presented split-dose regimen neutropenia grade 3 and 4 was observed in 31.6% of responders. In comparison, the two large phase III studies with a standard TPF regimen observed this hematologic toxicity in 38% and 76% of the cases, respectively [24] . The split-dose regime did not lead to treatment delays as it was also shown for a comparable split-dose strategy in gastric cancer [7] . It might be also a feasible strategy for further clinical trials to omit fluorouracil. This might allow higher dosages of docetaxel [24] .
Using the chemoselection concept, the outcome of the present phase II was remarkable: responders reached a PFS rate after 24 months of 88.5% compared with 60.6% for non-responders. Responders with oropharyngeal cancer had a PFS rate of even 91.8% compared with 86.7% in responders with oral cancer. Zhong et al. report a disease-free survival rate of about 65% after 24 months for patients with oral cancer with and without TPF ICT before surgery and postoperative radiotherapy [5] . The conclusion is that split-dose TPF does not compromise the effectivity of surgery and postoperative radiotherapy only. Chemoselection in combination with split-dose TPF seems at least to select out prognostically good patients and seems to lead to good oncological results.
In conclusion, the presented results show that chemoselection with short ICT seems to be a strategy for fast selection of patients profiting from TPF (responders) and sparing toxicity for patients not profiting (non-responders). The split TPF regimen can be safely combined with surgery and postoperative radiotherapy or radiochemotherapy. The good feasibility and outcome of the tri-modal concept offers evidence for an additional investigation in a phase III study. This randomized phase III study should compare patients to one arm with ICT with a decision based on first cycle response followed by surgery and radiochemotherapy to patients in the other arm randomized to surgery followed by radiochemotherapy only. Alternatively, a third arm with definitive radiochemotherapy could be added, or a focus could be placed on the non-responders by selecting non-responders for more intense radiochemotherapy.
